Rare Thyroid Therapeutics
www.rarethyroid.comRare Thyroid Therapeutics is a privately held pharmaceutical company, developing therapies for rare and neglected thyroid hormone disorders. Our lead product candidate Emcitate® is under development for the treatment of MCT8 deficiency, also called Allan-Herndon-Dudley Syndrome, a rare inborn X-linked disorder caused by a dysfunctional thyroid hormone transporter.
Read more
Rare Thyroid Therapeutics is a privately held pharmaceutical company, developing therapies for rare and neglected thyroid hormone disorders. Our lead product candidate Emcitate® is under development for the treatment of MCT8 deficiency, also called Allan-Herndon-Dudley Syndrome, a rare inborn X-linked disorder caused by a dysfunctional thyroid hormone transporter.
Read more
Country
City (Headquarters)
Stockholm
Industry
Employees
1-10
Founded
2017
Social
Employees statistics
View all employeesPotential Decision Makers
Chief Executive Officer and Board Member Rare Thyroid Therapeutics Ab
Email ****** @****.comPhone (***) ****-****
Technologies
(13)
